Develops small-molecule treatments for people with inherited diseases caused by repeated genetic sequences, including Friedreich ataxia, Fuchs endothelial corneal dystrophy and myotonic dystrophy.
10-K for FY2025, filed Mar 9, 2026We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of…View ↗
We utilize our proprietary GeneTAC® platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide…View ↗
We are developing a portfolio of GeneTAC® product candidates designed to address genetic diseases driven by inherited nucleotide repeat…View ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
−$20.3MView ↗
Competes with Larimar Therapeutics, Lexeo Therapeutics, Minoryx Therapeutics, PTC Therapeutics, Solid Biosciences, Capsida Biotherapeutics, Papillon Therapeutics, Voyager Therapeutics, Aurion Biotech, Emmecell, Kowa Pharmaceutical, Santen Pharmaceutical, Trefoil Therapeutics, AMO Pharma, Arrowhead Pharmaceuticals, Arthex Biotech, Avidity Biosciences, Dyne Therapeutics, EditForce, and Harmony Biosciences
10-K for FY2025, filed Mar 9, 2026Friedreich Ataxia. In February 2023, the FDA approved omaveloxolone, a Nrf2 activator, for the treatment of FA in adults and adolescents…View ↗
Loading...